Free Trial
NASDAQ:AXGN

AxoGen (AXGN) Stock Price, News & Analysis

AxoGen logo
$13.95
-0.05 (-0.36%)
(As of 11/1/2024 ET)

About AxoGen Stock (NASDAQ:AXGN)

Key Stats

Today's Range
$13.89
$14.24
50-Day Range
$12.65
$14.71
52-Week Range
$3.56
$15.23
Volume
259,545 shs
Average Volume
397,170 shs
Market Capitalization
$611.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

AxoGen Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
21st Percentile Overall Score

AXGN MarketRank™: 

AxoGen scored higher than 21% of companies evaluated by MarketBeat, and ranked 889th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AxoGen has only been the subject of 1 research reports in the past 90 days.

  • Read more about AxoGen's stock forecast and price target.
  • Earnings Growth

    Earnings for AxoGen are expected to grow in the coming year, from ($0.33) to ($0.18) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AxoGen is -36.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AxoGen is -36.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AxoGen has a P/B Ratio of 6.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AxoGen's valuation and earnings.
  • Percentage of Shares Shorted

    2.81% of the outstanding shares of AxoGen have been sold short.
  • Short Interest Ratio / Days to Cover

    AxoGen has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AxoGen has recently increased by 1.65%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    AxoGen does not currently pay a dividend.

  • Dividend Growth

    AxoGen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.81% of the outstanding shares of AxoGen have been sold short.
  • Short Interest Ratio / Days to Cover

    AxoGen has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AxoGen has recently increased by 1.65%, indicating that investor sentiment is decreasing.
  • News Sentiment

    AxoGen has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for AxoGen this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AxoGen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of AxoGen is held by insiders.

  • Percentage Held by Institutions

    80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AxoGen's insider trading history.
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Stock News Headlines

Nvidia warning urgent
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
AxoGen: An Intriguing Growth Story
ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc
AxoGen, Inc. (NASDAQ:AXGN): Are Analysts Optimistic?
See More Headlines

AXGN Stock Analysis - Frequently Asked Questions

AxoGen's stock was trading at $6.83 at the beginning of 2024. Since then, AXGN shares have increased by 104.2% and is now trading at $13.95.
View the best growth stocks for 2024 here
.

AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings results on Thursday, August, 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The medical equipment provider had revenue of $47.91 million for the quarter, compared to analysts' expectations of $43.27 million. AxoGen had a negative trailing twelve-month return on equity of 17.30% and a negative net margin of 9.53%.

Top institutional investors of AxoGen include Perkins Capital Management Inc. (0.65%), Rice Hall James & Associates LLC (0.44%), Exchange Traded Concepts LLC (0.17%) and Semanteon Capital Management LP (0.10%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Guido J Neels, Peter J Mariani, Michael Patrick Donovan and William P Mr Burke.
View institutional ownership trends
.

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/08/2024
Today
11/02/2024
Next Earnings (Confirmed)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AXGN
Employees
426
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$20.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+7.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-21,720,000.00
Pretax Margin
-9.53%

Debt

Sales & Book Value

Annual Sales
$159.01 million
Book Value
$2.22 per share

Miscellaneous

Free Float
40,762,000
Market Cap
$611.43 million
Optionable
Optionable
Beta
1.13

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AXGN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners